糖尿病の非インスリン療法の世界市場レポート 2025年

糖尿病の非インスリン療法市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.8%で279億米ドルに成長します。予測期間における成長の背景には、糖尿病有病率の上昇、糖尿病管理に対する意識の高まり、併用療法の採用拡大、高齢者人口の拡大、ヘルスケア支出の増加、遠隔医療の拡大、経口薬への嗜好の高まりなどがあります。予測期間における主な動向としては、経口薬と注射薬の進歩、ドラッグデリバリーシステムの進歩、経口ペプチドデリバリーの進歩、遠隔医療とデジタルヘルスソリューションの採用、併用療法の進歩などが挙げられます。

糖尿病有病率の上昇は、今後の糖尿病非インスリン療法市場の成長を促進すると予想されます。糖尿病は血糖値の上昇を特徴とする慢性疾患で、体内でインスリンが十分に分泌されないか、分泌されたインスリンを適切に利用できない場合に発症します。糖尿病患者の増加は、座りがちなライフスタイル、不健康な食生活、遺伝的素因、高齢化、肥満、民族性、認識不足、ヘルスケアへのアクセス制限、環境要因に関連しています。糖尿病の非インスリン療法は、インスリン感受性を高め、肝臓でのグルコース産生を低下させ、筋肉細胞でのグルコース取り込みを促進し、全体的な血糖コントロールを改善することにより、病態を管理する助けとなります。例えば、2023年4月、英国の糖尿病慈善団体である英国糖尿病協会の報告によると、英国では430万人が糖尿病と診断されました。2021-22年の登録データでは、2020-21年と比較して14万8,951件増加しており、240万人以上が2型糖尿病を発症するリスクが高いです。その結果、糖尿病有病率の増加が糖尿病非インスリン療法市場の拡大を牽引しています。

非インスリン療法市場の主要企業は、リアルタイムのモニタリング、データ分析、カスタマイズされた治療計画を通じて患者の転帰を改善する個別化糖尿病管理システムに注力しています。個別化システムは、患者個々のニーズに基づいて治療戦略とモニタリングを適応させ、リアルタイムデータと分析を活用して治療を最適化します。例えば、イーライリリー・アンド・カンパニーは2022年11月にTempoパーソナライズド糖尿病管理プラットフォームを発表しました。このプラットフォームは、Tempoスマートボタン、TempoSmartアプリ、プレフィルドインスリンペン（Tempo Pen）を統合し、成人の糖尿病患者にオーダーメイドのガイダンスを提供します。この技術は、1型および2型糖尿病患者とそのヘルスケアプロバイダーの両方が、リリーのインスリンを使用して、情報に基づいたデータ駆動型の治療決定を行うことを支援します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界糖尿病の非インスリン療法PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の糖尿病の非インスリン療法市場：成長率分析
• 世界の糖尿病の非インスリン療法市場の実績：規模と成長, 2019-2024
• 世界の糖尿病の非インスリン療法市場の予測：規模と成長, 2024-2029, 2034F
• 世界糖尿病の非インスリン療法総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の糖尿病の非インスリン療法市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ビグアナイド
• スルホニル尿素
• チアゾリジンジオン
• α-グルコシダーゼ阻害剤
• ジペプチジルペプチダーゼ-4（DPP-4）阻害剤
• グルカゴン様ペプチド-1（GLP-1）類似体
• ナトリウム・グルコース共輸送体2（SGLT2）阻害剤
• 世界の糖尿病の非インスリン療法市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 筋肉内
• 世界の糖尿病の非インスリン療法市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売薬局
• 病院薬局
• オンライン薬局
• 世界の糖尿病の非インスリン療法市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 監視
• 診断
• 治療
• その他の用途
• 世界の糖尿病の非インスリン療法市場ビグアナイド薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトホルミン
• メトホルミンと他の薬剤の併用
• 世界の糖尿病の非インスリン療法市場スルホニル尿素剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• グリメピリド
• グリピジド
• グリブリド
• 世界の糖尿病の非インスリン療法市場チアゾリジンジオンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ピオグリタゾン
• ロシグリタゾン
• 世界の糖尿病の非インスリン療法市場、α-グルコシダーゼ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アカルボース
• ミグリトール
• 世界の糖尿病の非インスリン療法市場ジペプチジルペプチダーゼ-4（DPP-4）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シタグリプチン
• サグリプチン
• リナグリプチン
• アログリプチン
• 世界の糖尿病の非インスリン療法市場グルカゴン様ペプチド-1（GLP-1）類似体のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エキセナチド
• リラグルチド
• デュラグルチド
• セマグルチド
• 世界の糖尿病の非インスリン療法市場ナトリウム・グルコース共輸送体2（SGLT2）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カナグリフロジン
• ダパグリフロジン
• エンパグリフロジン

第7章 地域別・国別分析

• 世界の糖尿病の非インスリン療法市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の糖尿病の非インスリン療法市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 糖尿病の非インスリン療法市場：競合情勢
• 糖尿病の非インスリン療法市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Novartis AG
• GSK plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Novo Nordisk A/S
• Boehringer Ingelheim International GmbH
• Les Servier Laboratories
• Sumitomo Dainippon Pharma Co. Ltd.
• Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
• Uni-Bio Science Group Ltd.
• Intarcia Therapeutics
• Janssen Pharmaceuticals
• Boan Biotech
• SatRx LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 糖尿病の非インスリン療法市場2029：新たな機会を提供する国
• 糖尿病の非インスリン療法市場2029：新たな機会を提供するセグメント
• 糖尿病の非インスリン療法市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Non-insulin therapies for diabetes are treatments and medications designed to manage blood sugar levels in diabetic patients without the need for insulin injections. These therapies play a crucial role in regulating blood glucose levels for patients who either do not require insulin or prefer alternative methods of treatment.

The primary classes of drugs in the non-insulin therapies for diabetes market include biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Biguanides, for instance, are oral hypoglycemic agents that target type 2 diabetes by reducing liver glucose production and improving insulin sensitivity. These medications can be administered orally or intramuscularly and are distributed through various channels such as retail pharmacies, hospital pharmacies, and online pharmacies. They are utilized for purposes such as monitoring, diagnosis, treatment, and more.

The non-insulin therapies for diabetes market research report is one of a series of new reports from The Business Research Company that provides non-insulin therapies for diabetes market statistics, including the non-insulin therapies for diabetes industry global market size, regional shares, competitors with non-insulin therapies for diabetes market share, detailed non-insulin therapies for diabetes market segments, market trends, and opportunities, and any further data you may need to thrive in the non-insulin therapies for diabetes industry. These non-insulin therapies for diabetes market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-insulin therapies for diabetes market size has grown strongly in recent years. It will grow from $19.98 billion in 2024 to $21.41 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing diabetes prevalence, increasing awareness of diabetes management, rise in healthcare expenditure, shift in lifestyle changes leading to higher incidence rates, surge in diagnosis, increasing government initiatives for diabetes care, and increasing investment in pharmaceutical R&D.

The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to $27.9 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing awareness of diabetes management, growing adoption of combination therapies, expanding geriatric population, increasing healthcare expenditure, expansion of telemedicine, and growing preference for oral medications. Major trends in the forecast period include advancements in oral and injectable medications, advancements in drug delivery systems, advancements in oral peptide delivery, adoption of telemedicine and digital health solutions, and advancements in combination therapies.

The rising prevalence of diabetes is anticipated to drive the growth of the non-insulin therapies market for diabetes in the future. Diabetes is a chronic condition marked by elevated blood glucose (sugar) levels, occurring when the body cannot produce adequate insulin or properly utilize the insulin it produces. The increase in diabetes cases is linked to sedentary lifestyles, unhealthy diets, genetic predisposition, aging populations, obesity, ethnicity, lack of awareness, limited healthcare access, and environmental factors. Non-insulin therapies for diabetes aid in managing the condition by enhancing insulin sensitivity, lowering glucose production in the liver, boosting glucose uptake in muscle cells, and improving overall glycemic control. For example, in April 2023, a report from The British Diabetic Association, a UK-based diabetes charity, indicated that 4.3 million people in the UK had been diagnosed with diabetes. Registration data for 2021-22 reflected a rise of 148,951 cases compared to 2020-21, with over 2.4 million individuals at high risk of developing type 2 diabetes. Consequently, the growing prevalence of diabetes is driving the expansion of the non-insulin therapies market for diabetes.

Leading companies in the non-insulin therapies market are focusing on personalized diabetes management systems to improve patient outcomes through real-time monitoring, data analysis, and customized treatment plans. Personalized systems adapt treatment strategies and monitoring based on individual patient needs, leveraging real-time data and analytics to optimize care. For instance, Eli Lilly and Company introduced the Tempo personalized diabetes management platform in November 2022. This platform integrates the Tempo Smart Button, TempoSmart app, and prefilled insulin pen (Tempo Pen) to deliver tailored guidance for adults with diabetes. The technology assists both type 1 and type 2 diabetes patients and their healthcare providers in making informed, data-driven treatment decisions using Lilly insulins.

In August 2023, Eli Lilly and Company acquired Sigilon Therapeutics Inc. for $309.6 million, enhancing its research and development efforts in encapsulated cell therapies such as SIG-002 for type 1 diabetes treatment. This acquisition reflects Lilly's commitment to advancing solutions that alleviate the continuous disease management burden for individuals with type 1 diabetes. Sigilon Therapeutics Inc. is a biopharmaceutical company specializing in encapsulated cell therapies for type 1 diabetes treatment.

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-insulin therapies for diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-insulin therapies for diabetes market consist of sales of glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, oral medications such as metformin and sulfonylureas, and injectable medications such as glp-1 receptor agonists. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Insulin Therapies For Diabetes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-insulin therapies for diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-insulin therapies for diabetes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-insulin therapies for diabetes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Biguanides; Sulfonylureas; Thiazolidinedione's; Alpha-Glucosidase Inhibitors; Dipeptidyl peptidase-4 (DPP-4) Inhibitors; Glucagon-like peptide-1 (GLP-1) Analogs; Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
• 2) By Route Of Administration: Oral; Intramuscular
• 3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
• 4) By Application: Monitoring; Diagnosis; Treatment; Other Applications
• Subsegments:
• 1) By Biguanides: Metformin; Combination Of Metformin With Other Drugs
• 2) By Sulfonylureas: Glimepiride; Glipizide; Glyburide
• 3) By Thiazolidinediones: Pioglitazone; Rosiglitazone
• 4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol
• 5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
• 6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide; Liraglutide; Dulaglutide; Semaglutide
• 7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi; The Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-Insulin Therapies For Diabetes Market Characteristics

3. Non-Insulin Therapies For Diabetes Market Trends And Strategies

4. Non-Insulin Therapies For Diabetes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Non-Insulin Therapies For Diabetes Growth Analysis And Strategic Analysis Framework

• 5.1. Global Non-Insulin Therapies For Diabetes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Non-Insulin Therapies For Diabetes Market Growth Rate Analysis
• 5.4. Global Non-Insulin Therapies For Diabetes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Non-Insulin Therapies For Diabetes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Non-Insulin Therapies For Diabetes Total Addressable Market (TAM)

6. Non-Insulin Therapies For Diabetes Market Segmentation

• 6.1. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biguanides
• Sulfonylureas
• Thiazolidinedione's
• Alpha-Glucosidase Inhibitors
• Dipeptidyl peptidase-4 (DPP-4) Inhibitors
• Glucagon-like peptide-1 (GLP-1) Analogs
• Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
• 6.2. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intramuscular
• 6.3. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy
• 6.4. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monitoring
• Diagnosis
• Treatment
• Other Applications
• 6.5. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metformin
• Combination Of Metformin With Other Drugs
• 6.6. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glimepiride
• Glipizide
• Glyburide
• 6.7. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Thiazolidinediones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pioglitazone
• Rosiglitazone
• 6.8. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acarbose
• Miglitol
• 6.9. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sitagliptin
• Saxagliptin
• Linagliptin
• Alogliptin
• 6.10. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Glucagon-Like Peptide-1 (GLP-1) Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exenatide
• Liraglutide
• Dulaglutide
• Semaglutide
• 6.11. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Canagliflozin
• Dapagliflozin
• Empagliflozin

7. Non-Insulin Therapies For Diabetes Market Regional And Country Analysis

• 7.1. Global Non-Insulin Therapies For Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Non-Insulin Therapies For Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Insulin Therapies For Diabetes Market

• 8.1. Asia-Pacific Non-Insulin Therapies For Diabetes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Insulin Therapies For Diabetes Market

• 9.1. China Non-Insulin Therapies For Diabetes Market Overview
• 9.2. China Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Insulin Therapies For Diabetes Market

• 10.1. India Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Insulin Therapies For Diabetes Market

• 11.1. Japan Non-Insulin Therapies For Diabetes Market Overview
• 11.2. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Insulin Therapies For Diabetes Market

• 12.1. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Insulin Therapies For Diabetes Market

• 13.1. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Insulin Therapies For Diabetes Market

• 14.1. South Korea Non-Insulin Therapies For Diabetes Market Overview
• 14.2. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Insulin Therapies For Diabetes Market

• 15.1. Western Europe Non-Insulin Therapies For Diabetes Market Overview
• 15.2. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Insulin Therapies For Diabetes Market

• 16.1. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Insulin Therapies For Diabetes Market

• 17.1. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Insulin Therapies For Diabetes Market

• 18.1. France Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Insulin Therapies For Diabetes Market

• 19.1. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Insulin Therapies For Diabetes Market

• 20.1. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Insulin Therapies For Diabetes Market

• 21.1. Eastern Europe Non-Insulin Therapies For Diabetes Market Overview
• 21.2. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Insulin Therapies For Diabetes Market

• 22.1. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Insulin Therapies For Diabetes Market

• 23.1. North America Non-Insulin Therapies For Diabetes Market Overview
• 23.2. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Insulin Therapies For Diabetes Market

• 24.1. USA Non-Insulin Therapies For Diabetes Market Overview
• 24.2. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Insulin Therapies For Diabetes Market

• 25.1. Canada Non-Insulin Therapies For Diabetes Market Overview
• 25.2. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Insulin Therapies For Diabetes Market

• 26.1. South America Non-Insulin Therapies For Diabetes Market Overview
• 26.2. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Insulin Therapies For Diabetes Market

• 27.1. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Insulin Therapies For Diabetes Market

• 28.1. Middle East Non-Insulin Therapies For Diabetes Market Overview
• 28.2. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Insulin Therapies For Diabetes Market

• 29.1. Africa Non-Insulin Therapies For Diabetes Market Overview
• 29.2. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Insulin Therapies For Diabetes Market Competitive Landscape And Company Profiles

• 30.1. Non-Insulin Therapies For Diabetes Market Competitive Landscape
• 30.2. Non-Insulin Therapies For Diabetes Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Non-Insulin Therapies For Diabetes Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Novartis AG
• 31.3. GSK plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly and Company
• 31.6. Novo Nordisk A/S
• 31.7. Boehringer Ingelheim International GmbH
• 31.8. Les Servier Laboratories
• 31.9. Sumitomo Dainippon Pharma Co. Ltd.
• 31.10. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
• 31.11. Uni-Bio Science Group Ltd.
• 31.12. Intarcia Therapeutics
• 31.13. Janssen Pharmaceuticals
• 31.14. Boan Biotech
• 31.15. SatRx LLC

32. Global Non-Insulin Therapies For Diabetes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Insulin Therapies For Diabetes Market

34. Recent Developments In The Non-Insulin Therapies For Diabetes Market

35. Non-Insulin Therapies For Diabetes Market High Potential Countries, Segments and Strategies

• 35.1 Non-Insulin Therapies For Diabetes Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Non-Insulin Therapies For Diabetes Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Non-Insulin Therapies For Diabetes Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer